

INTERIM FINANCIAL STATEMENTS FOR THE FIRST QUARTER ENDED 31 MARCH 2014 (THE FIGURES HAVE NOT BEEN AUDITED)

CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME FOR THE PERIOD ENDED 31 MARCH 2014

		3 MONTHS ENDED		PERIOD ENDED	
	Note	31/03/2014	31/03/2013	31/03/2014	31/03/2013
	_	RM'000	RM'000	RM'000	RM'000
Revenue		130,927	106,359	130,927	106,359
Cost of sales		(99,050)	(78,033)	(99,050)	(78,033)
Gross profit		31,877	28,326	31,877	28,326
Other income		972	1,029	972	1,029
Selling & marketing expenses		(15,144)	(12,406)	(15,144)	(12,406)
Administrative expenses		(5,038)	(4,425)	(5,038)	(4,425)
Other expenses		(189)	(201)	(189)	(201)
Finance cost		(3)	(10)	(3)	(10)
Share of results of joint venture		147	(116)	147	(116)
Profit before tax	A7	12,622	12,197	12,622	12,197
Income tax expense	B6	(3,154)	(3,063)	(3,154)	(3,063)
Net profit for the period	_	9,468	9,134	9,468	9,134
Other comprehensive income:					
Exchange differences on translation of foreign operations, net of tax		-	-	-	-
Total comprehensive income for the period	_	9,468	9,134	9,468	9,134
Net profit attributable to:					
Owners of the parent		9,438	9,113	9,438	9,113
Non-controlling interest		30	21	30	21
Net profit for the period	_	9,468	9,134	9,468	9,134
Total comprehensive income attributable to:					
Owners of the parent		9,438	9,113	9,438	9,113
Non-controlling interest	_	30	21	30	21
Total comprehensive income for the period	_	9,468	9,134	9,468	9,134
Earnings per share attributable to owners of the					
parent:		Sen	Sen	Sen	Sen
- Basic	B11	10.07	9.72	10.07	9.72
- Diluted	B11	10.07	9.72	10.07	9.72

The Condensed Consolidated Statement of Comprehensive Income should be read in conjunction with the accompanying explanatory notes attached to the Interim Financial Statements.



INTERIM FINANCIAL STATEMENTS FOR THE FIRST QUARTER ENDED 31 MARCH 2014 (THE FIGURES HAVE NOT BEEN AUDITED)

CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION AS AT 31 MARCH 2014

	Note	As at 31/03/2014 RM'000	As at 31/12/2013 RM'000
	-		(Audited)
ASSETS			
Non-Current Assets			
Property, plant and equipment	A12	105,688	106,921
Investment properties		3,312	3,329
Intangible assets		1,178	1,190
Investment in a joint venture		4,357	4,211
Deferred tax assets		461	376
Receivables		5,000	5,000
Long term investment	-	5,520	5,520
	-	125,516	126,547
Current Assets		50 557	47 740
Inventories		50,557	47,742
Receivables		123,898	101,324
Prepayments Tou measure la		554 252	120
Tax recoverable		353	482
Available-for-sale financial asset	A 15 9 D 12	-	3,928
Derivative financial instruments	A15 & B12	15	25
Deposits, bank and cash balances	-	38,221	32,804
	-	213,598	186,425
TOTAL ASSETS	=	339,114	312,972
EQUITY AND LIABILITIES			
Current Liabilities Borrowings	B8	11	
Derivative financial instruments	A15 & B12	2	- 1
Payables	A15 & D12	2 86,097	70,374
Current tax payable		2,913	1,771
Current tax payable	-	89,023	72,146
Non-Current Liabilities	-	89,025	72,140
Borrowings	B8	41	-
Deferred tax liabilities		5,508	5,752
	-	5,549	5,752
TOTAL LIABILITIES	-	94,572	77,898
	-	,	
NET ASSETS	=	244,542	235,074
EQUITY			
Equity attributable to owners of the parent			
Share capital		93,717	93,717
Reserves		3,218	3,218
Retained earnings	B14	147,334	137,896
	-	244,269	234,831
Non-controlling interest		273	243
TOTAL EQUITY	-	244,542	235,074
	=		
		RM	RM
Net Assets per share attributable to owners of the parent	-	2.61	2.51
r i i i i i i i i i i i i i i i i i i i	=		

The Condensed Consolidated Statement of Financial Position should be read in conjunction with the accompanying explanatory notes attached to the Interim Financial Statements.



(4/3)

(Incorporated in Malaysia)

INTERIM FINANCIAL STATEMENTS FOR THE FIRST QUARTER ENDED 31 MARCH 2014 (THE FIGURES HAVE NOT BEEN AUDITED)

CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY FOR THE CUMULATIVE PERIOD ENDED 31 MARCH 2014

	<		ibutable <u>D</u> i	istributable	Equity attributable to owners of	Non-	
			reign currency	Retained	the parent,	controlling	Total
		Capital	translation	Earnings	total	Interest	Equity
	Note	RM'000	reserve RM'000	RM'000	RM'000	RM'000	RM'000
PERIOD ENDED 31 MARCH 2014							
Balance at 1 January 2014		93,717	3,218	137,896	234,831	243	235,074
Total comprehensive income		-	-	9,438	9,438	30	9,468
-							
Transaction with owners							
Dividends on ordinary shares	A8	-	-	-	-	-	-
Balance as at 31 March 2014	_	93,717	3,218	147,334	244,269	273	244,542
PERIOD ENDED 31 MARCH 2013							
Balance at 1 January 2013		93,717	1,364	121,229	216,310	142	216,452
Total comprehensive income		-	-	9,113	9,113	21	9,134
Transaction with owners							
Dividends on ordinary shares	A8						_
Structures on ordinary shares	110						
Balance as at 31 March 2013	_	93,717	1,364	130,342	225,423	163	225,586

The Condensed Consolidated Statement of Changes in Equity should be read in conjunction with the accompanying explanatory notes attached to the Interim Financial Statements.



INTERIM FINANCIAL STATEMENTS FOR THE FIRST QUARTER ENDED 31 MARCH 2014 (THE FIGURES HAVE NOT BEEN AUDITED)

CONDENSED CONSOLIDATED STATEMENT OF CASH FLOW FOR THE CUMULATIVE PERIOD ENDED 31 MARCH 2014

	PERIOD ENDED	
	31/03/2014 RM'000	31/03/2013 RM'000
Operating activities		
Profit before tax	12,622	12,197
Adjustments for:		
Depreciation and amortisation	2,246	1,864
Net profit on disposal of property, plant and equipment	(77)	-
Share of results of joint venture	(147)	116
Net profit on disposal of available-for-sale financial asset	(297)	-
Fair value changes of investment securities	-	(419)
Fair value changes of derivative financial instruments	11	22
Inventories written off and written down	65	47
Impairment loss /(reversal of impairment loss) on trade receivables	57	(15)
Interest expense	3	10
Interest income	(91)	(66)
Operating cash flows before changes in working capital	14,392	13,756
Inventories	(2,880)	(2,956)
Receivables	(23,065)	(11,673)
Payables	15,723	6,452
Cash generated from operations	4,170	5,579
Tax paid	(2,211)	(2,297)
Net cash flows generated from operating activities	1,959	3,282
Investing activities		0,202
Proceeds from the disposal of available-for-sale financial asset	4,225	-
Investment in joint venture	-	(4,988)
Purchase of property, plant and equipment & intangible assets	(984)	(1,255)
Proceeds from disposal of property, plant and equipment	77	-
Interest received	91	66
Net cash flows generated from /(used in) investing activities	3,409	(6,177)
Financing activities		(0,177)
Finance lease raised	52	_
Dividends paid	52	
Other financing activities paid	(3)	(10)
Net cash flows generated from /(used in) financing activities	<u> </u>	
ret cash nows generated nom (used m) mancing activities		(10)
Net increase /(decrease) in cash and cash equivalents	5,417	(2,905)
Cash and cash equivalents at 1 January	32,804	34,675
Effect of exchange rate changes on cash and cash equivalents	-	-
Cash and cash equivalents at the end of the financial period	38,221	31,770



APEX HEALTHCARE BERHAD (473108-T)

(Incorporated in Malaysia)

INTERIM FINANCIAL STATEMENTS FOR THE FIRST QUARTER ENDED 31 MARCH 2014 (THE FIGURES HAVE NOT BEEN AUDITED)

A NOTES PURSUANT TO MFRS 134 FOR THE PERIOD ENDED 31 MARCH 2014

A1 Basis of preparation

These unaudited condensed consolidated interim financial statements for the period ended 31 March 2014 have been prepared in accordance with MFRS 134 Interim Financial Reporting and paragraph 9.22 of the Listing Requirements of Bursa Malaysia Securities Berhad. These unaudited condensed consolidated interim financial statements also comply with IAS 34 Interim Financial Reporting issued by the International Accounting Standards Board. It should be read in conjunction with the Group's most recent audited financial statements for the year ended 31 December 2013.

These unaudited condensed consolidated interim financial statements have been prepared on a historical cost basis except for the certain financial assets and liabilities classified as financial assets and liabilities at fair value through profit or loss and financial assets designated as available for sale.

A2 Significant accounting policies

The significant accounting policies adopted in preparing these unaudited condensed consolidated interim financial statements are consistent with those of the audited financial statements for the year ended 31 December 2013 except for the adoption of the following Malaysian Financial Reporting Standards ("MFRS") and Issues Committee ("IC") Interpretations wherever applicable to the Group and Company:

	Effective for annual
	periods beginning
Description	on or after
Amendments to MFRS 132: Offsetting Financial Assets and Financial Liabilities	1 January 2014
Amendments to MFRS 10, MFRS 12 and MFRS 127: Investment Entities	1 January 2014
Amendments to MFRS 136: Recoverable Amount Disclosures for Non-Financial Assets	1 January 2014
Amendments to MFRS 139: Novation of Derivatives and Continuation of Hedge Accounting	1 January 2014
IC Interpretation 21 Levies	1 January 2014
Amendments to MFRS 119: Defined Benefit Plans: Employee Contributions	1 July 2014
Annual Improvements to MFRSs 2010–2012 Cycle	1 July 2014
Annual Improvements to MFRSs 2011–2013 Cycle	1 July 2014
MFRS 9 Financial Instruments (IFRS 9 issued by IASB in November 2009)	To be announced
MFRS 9 Financial Instruments (IFRS 9 issued by IASB in October 2010)	To be announced
MFRS 9 Financial Instruments: Hedge Accounting and amendments to MFRS 9, MFRS 7 and MFRS 139	To be announced

The directors expect that the adoption of the above standards and interpretations will have no material impact on the financial statements in the period of initial application except as discussed below:

MFRS 9 Financial Instruments: Classification and Measurement

MFRS 9 reflects the first phase of work on the replacement of MFRS 139 and applies to classification and measurement of financial assets and financial liabilities as defined in MFRS 139. The standard was initially effective for annual periods beginning on or after 1 January 2013, but Amendments to MFRS 9: Mandatory Effective Date of MFRS 9 and Transition Disclosures, issued in March 2012, moved the mandatory effective date to 1 January 2015. Subsequently, on 14 February 2014, it was announced that the new effective date will be decided when the project is closer to completion. The adoption of the first phase of MFRS 9 will have an effect on the classification and measurement of the Group's financial assets, but will not have an impact on classification and measurements of the Group's financial liabilities. The Group will quantify the effect in conjunction with the other phases, when the final standard including all phases is issued.

A3 Seasonality or cyclicality of interim operations

The Group's interim operations are not affected materially by any seasonal or cyclical factors.

A4 Unusual items

There were no unusual items that affected the assets, liabilities, equity, net income or cash flows for the period ended 31 March 2014.

A5 <u>Changes in estimates of amounts reported in prior interim periods of the current financial year or in prior financial year.</u> There were no changes in estimates of amounts reported in the prior interim periods of the current financial year or prior financial year.

A6 Issuances, cancellations, repurchases, resale and repayments of debt and equity securities

There were no issuance and/or repayment of debt and equity securities, share buy-backs, share cancellations, shares held as treasury shares and resale of treasury shares during the period ended 31 March 2014.



INTERIM FINANCIAL STATEMENTS FOR THE FIRST QUARTER ENDED 31 MARCH 2014 (THE FIGURES HAVE NOT BEEN AUDITED)

A NOTES PURSUANT TO MFRS 134 FOR THE YEAR ENDED 31 MARCH 2014 (continued)

A7 Profit before tax	3 MONTHS ENDED		PERIOD ENDED		
Included in profit before tax are the following items:	31/03/2014	31/03/2013	31/03/2014	31/03/2013	
	RM'000	RM'000	RM'000	RM'000	
Interest income	91	66	91	66	
Other income including investment income	324	506	324	506	
Interest expense	(3)	(10)	(3)	(10)	
Depreciation and amortisation	(2,246)	(1,864)	(2,246)	(1,864)	
Impairment loss /(reversal of impairment loss) on trade receivables	(57)	15	(57)	15	
Inventories written off and written down	(65)	(47)	(65)	(47)	
Net profit on disposal of property, plant and equipment	77	-	77	-	
Fair value gain of investment securities	-	419	-	419	
Fair value gain/(loss) of derivative financial instruments	(11)	(22)	(11)	(22)	
Foreign exchange gains less losses	139	-	139	-	
Exceptional items	_	-	-	-	

A8 Dividends paid and declared

There were no dividends paid during the current period ended 31 March 2014.

A9 Segment Information

The Group is organised into three main business units based on their activities, and has three reportable operating segments as follows:

(i) Manufacturing and marketing of pharmaceutical products;

- (ii) Wholesale and distribution of pharmaceutical and healthcare products; and
- (iii) Corporate comprising investments in retail pharmacy business and properties and the provision of management services.

OPERATING SEGMENTS	Manufacturin g and Marketing	Wholesale and Distribution	Corporate	Adjustments and eliminations	GROUP
PERIOD ENDED 31/03/2014	RM'000	RM'000	RM'000	RM'000	RM'000
External Revenue	7,788	121,242	1,897	-	130,927
Inter-segment revenue	21,869	-	13,055	(34,924)	-
Total Revenue	29,657	121,242	14,952	(34,924)	130,927
Segment Results (external)	9,279	5,169	(1,341)	(482)	12,625
Finance costs					(3)
Profit before tax					12,622
PERIOD ENDED 31/03/2013	RM'000	RM'000	RM'000	RM'000	RM'000
External Revenue	5,782	98,886	1,691	-	106,359
Inter-segment revenue	19,837	192	980	(21,009)	-
Total Revenue	25,619	99,078	2,671	(21,009)	106,359
Segment Results (external)	8,648	4,911	(957)	(395)	12,207
Finance costs					(10)
Profit before tax					12,197
Segment assets					
31-Mar-2014	82,303	228,574	33,419	(5,182)	339,114
<u>31-Dec-2013</u>	81,719	207,715	28,675	(5,137)	312,972
Segment liabilities					
31-Mar-2014	(10,298)	(66,508)	(9,344)	(8,422)	(94,572)
31-Dec-2013	(8,166)	(58,820)	(3,389)	(7,523)	(77,898)

A10 Significant Events After the Reporting Date

There were no significant events that had arisen subsequent to the end of this current period.

A11 Changes in Group Composition

On 11 Feb 2014, the Company divested its entire 20% equity interest in Maritzberg Investments Ltd, which in turn owns 95% of P.T. Pentavalent, Indonesia, for a consideration of US\$ 1.3 million approximating RM 4.3 million. The divestment was completed on the same day.

Other than the above, the Group did not undertake any business combinations, acquisitions or disposals of subsidiaries and long-term investments, restructuring or discontinuation of operations during the current quarter ended 31 March 2014.



APEX HEALTHCARE BERHAD (473108-T)

(Incorporated in Malaysia)

INTERIM FINANCIAL STATEMENTS FOR THE FIRST QUARTER ENDED 31 MARCH 2014 (THE FIGURES HAVE NOT BEEN AUDITED)

A NOTES PURSUANT TO MFRS 134 FOR THE PERIOD ENDED 31 MARCH 2014 (continued)

A12 Property, plant and equipment

During the current quarter ended 31 March 2014, the Group acquired assets at a cost of RM 984,000 (31 March 2013: RM 1,249,000). Assets with carrying amount of RM 3 were disposed of by the Group during the current quarter ended 31 March 2014 (31 March 2013: RM nil), resulting in a net gain on disposal of RM 77,000 (31 March 2013: RM nil), recognised and included in other income in the statement of comprehensive income.

A13 Capital Commitments

Capital commitments of property, plant and equipment not provided for in the financial statements as at 31 March 2014 are as follows:

	RM'000
Authorised capital expenditure approved and contracted for	237
Authorised capital expenditure approved but not contracted for	11,553
	11,790

A14 Related Party Transactions

The Group does not have any significant transactions with related parties during the period ended 31 March 2014 in addition to the related party transactions disclosed in the audited financial statements for the year ended 31 December 2013.

A15 Fair value hierarchy

The Group uses the following leve	l of fair value hierarchy fo	or determining the fair value	of its financial instruments carried at fair value.
BBBBBB		8	

	31/03/2014	31/12/2013
Financial assets/(liabilities):	RM'000	RM'000
	(Leve	12)
Derivatives - Forward currency contracts	13	24

The Group classifies fair value measurement using a fair value hierarchy that reflects the significance of the inputs used in making the measurements. The fair value hierarchy has the following levels:

Level 1 – Quoted prices (unadjusted) in active markets for identical assets or liabilities;

Level 2 – Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly (i.e., as prices) or indirectly (i.e., derived from prices); and

Level 3 – Inputs for the asset or liability that are not based on observable market data (unobservable inputs).

There have been no transfers between the fair value hierarchy during the current interim period and financial year ended 2013.

A16 Changes in Contingent liabilities or Contingent assets.

There were no contingent liabilities or contingent assets of the Group since the end of the last annual reporting date.



INTERIM FINANCIAL STATEMENTS FOR THE FIRST QUARTER ENDED 31 MARCH 2014 (THE FIGURES HAVE NOT BEEN AUDITED)

B NOTES PURSUANT TO BURSA LISTING REQUIREMENTS: CHAPTER 9, APPENDIX 9B, PART A

B1 Detailed Performance Analysis of Operating Segments of the Group

In the first quarter of 2014, the Group achieved record revenue of RM 130.9 million and profit before tax of RM 12.6 million, growing 23% and 3% respectively when compared to the first quarter of 2013. Profit after tax was RM 9.5 million, rising 4% over that achieved in the first quarter of 2013.

Manufacturing and Marketing

Manufacturing and Marketing business unit returned a strong performance in the first quarter of 2014, with sales growing 16% over the same period last year. Sales to both private and government sectors in Malaysia were particularly robust, helped by sharpened sales and marketing strategies.

Wholesale and Distribution

Wholesale and Distribution business unit revenue grew 22% over the first quarter of 2013, due in large part to the commencement of new distribution agencies in Singapore and improvements in pharmaceutical wholesale in Malaysia. The continued strong sales momentum of own brand products ensured margins are maintained.

Corporate

Profit contribution from its joint venture amounted to RM 147,000 for the first quarter of 2014. Retail pharmacy sales at City Square Mall was 19% up compared to the same period in 2013. A new retail outlet will be opened at the redeveloped Komtar Johor Bahru City Centre Mall in the second quarter of 2014. Rental income was stable in the first quarter of this year.

B2 Material changes in the profit before tax for the quarter

Profit before tax for the current quarter was RM 12.6 million, an increase of 19% over the RM 10.6 million achieved in the last quarter of 2013. This is due to stronger sales performance in the first three months of 2014.

B3 Commentary

(a) <u>Prospects</u>

The continued strong performance of the Group's core businesses at the start of 2014 is the result of sound strategic planning and execution, continuous upgrading of manufacturing facilities, careful regional expansion, focused brand management, strategic new product launches and an emphasis on staff training and development.

The prospects for manufacturing, marketing and distribution of pharmaceuticals and consumer healthcare products remain good in the markets we operate. Market demand is underpinned by continual focus on generic drugs to reduce healthcare costs, affluent and informed consumers demanding quality and value in healthcare products and in certain countries, an ageing population.

The Group's entry into the contract manufacturing of orthopaedic devices for multinational customers enables it to add a new engine of growth for the future, increasing opportunities while diversifying risk. The newly acquired distribution warehouse in Singapore provides increased capacity to accommodate growth.

Barring unforeseen circumstances, the Board of Directors expects the Group to return another satisfactory performance in the remaining quarters of 2014.

- (b) <u>Progress to achieve forecast revenue or profit estimate</u> Not applicable.
- B4 <u>Statement by the Board of Directors' opinion on the achievability of forecast revenue or profit estimate</u> Not applicable.

B5 <u>Profit Forecast /Profit Guarantee</u>

Not applicable.

Income Tax Expense **3 MONTHS ENDED** PERIOD ENDED **B6** 31/03/2014 31/03/2013 31/03/2014 31/03/2013 RM'000 RM'000 **RM'000 RM'000** In respect of current period: income tax 3,483 3,086 3,483 3,086 deferred tax (329)(23)(329)(23)3,154 3,063 3,154 3,063 In respect of prior period: income tax 3,154 3,063 3,154 3,063

The effective tax rate for the current quarter and cumulative period was comparable with the statutory tax rate.



APEA HEALIHCARE BERHAD (4/51

(Incorporated in Malaysia)

INTERIM FINANCIAL STATEMENTS FOR THE FIRST QUARTER ENDED 31 MARCH 2014 (THE FIGURES HAVE NOT BEEN AUDITED)

B NOTES PURSUANT TO BURSA LISTING REQUIREMENTS: CHAPTER 9, APPENDIX 9B, PART A (continued)

B7 Status of Corporate Proposals

On 28 March 2014, the Company announced the proposed bonus issue of 23,429,218 new ordinary shares of RM1 each in the Company on the basis of one bonus share for every four existing shares held on an entitlement date to be determined later, by way of capitalizing fully from the Company's retained profits based on the audited financial statements of the Company as at 31 December 2013.

On 14 April 2014, Bursa Securities approved in principle the listing and quotation of the Bonus Shares on the Main Market of Bursa Securities pursuant to the proposed bonus issue which is now subjected to only the shareholders' approval at the forthcoming Extraordinary General Meeting.

Other than the above, there were no corporate proposals announced but not completed as at 14th May 2014.

B8 Group Borrowings and Debt Securities

	31/03/2014	31/12/2013
Current	RM'000	RM'000
Secured obligations under finance lease	11	-
Non-current		
Secured obligations under finance lease	41	-
Total	52	-
Obligations under finance lease denominated in foreign currency as at 31 March 2014:	SGD'000	RM'000
Singapore Dollars	20	-

The Group does not have any current or non-current debt securities denominated in Ringgit Malaysia or foreign currency as at 31 March 2014.

B9 Material Litigation

There is no pending material litigation at the date of this report.

B10 Dividend Payable

The Board of Directors does not recommend the payment of any interim dividend for the period ended 31 March 2014 (31 March 2013: Nil).

B11 Earnings per share

The following reflect the profit and share data used in the computation of basic and diluted earnings per share:

		3 MONTHS ENDED		PERIOD I	ENDED
		31/03/2014	31/03/2013	31/03/2014	31/03/2013
Basic Earnings per share					
Profit after tax	RM'000	9,438	9,113	9,438	9,113
Weighted average number of ordinary shares in issue	'000'	93,717	93,717	93,717	93,717
Basic earnings per share	sen	10.07	9.72	10.07	9.72
Diluted Earnings per share					
Profit after tax	RM'000	9,438	9,113	9,438	9,113
Weighted average number of ordinary shares in issue	'000'	93,717	93,717	93,717	93,717
Diluted earnings per share	sen	10.07	9.72	10.07	9.72

B12 Derivative Financial Instruments

(a) The Group's derivative financial instruments as at 31 March 2014 are as follows -

 Type of Derivatives	Contract /	Changes in Fair Value	
Forward Currency Contracts	Notional Amount RM'000	Assets RM'000	Liabilities RM'000
Less than 1 year			
Sale of goods	3,211	15	-
Purchase of goods	(1,139)	-	(2)
	2,072	15	(2)



APEX HEALTHCARE BERHAD (473108-T)

(Incorporated in Malaysia)

INTERIM FINANCIAL STATEMENTS FOR THE FIRST QUARTER ENDED 31 MARCH 2014 (THE FIGURES HAVE NOT BEEN AUDITED)

B NOTES PURSUANT TO BURSA LISTING REQUIREMENTS: CHAPTER 9, APPENDIX 9B, PART A (continued)

B12 Derivative Financial Instruments (continued)

- (b) The Group does not anticipate any market or credit risks arising from these derivatives.
- (c) The net cash requirements relating to these contracts was RM 2,072,000.
- (d) There have been no changes since the end of the previous financial year in respect of the following:

(i) the types of derivative contracts entered into and the rationale for entering into such contracts, as well as the expected benefits accruing from these contracts;

(ii) the risk management policies in place for mitigating and controlling the risks jointly-controlled entityd with these derivative contracts; and (iii) the related accounting policies.

B13 Fair Value Changes of Financial Liabilities

As at 31 March 2014, the Group does not have any significant financial liabilities measured at fair value through profit or loss other than the disclosure in note A15.

B14 Realised and Unrealised Profits/Losses Disclosure		Year ended
	31/03/2014	31/12/2013
	RM'000	RM'000
Total retained earnings of the Group:		
Realised	169,466	159,851
Unrealised	(2,686)	(3,204)
	166,780	156,647
Total share of results of joint venture		
Realised	(630)	(777)
	166,150	155,870
Less: Consolidation adjustments	(18,816)	(17,974)
Total Group's retained earnings as per consolidated accounts	147,334	137,896

B15 Auditors' report on preceding annual financial statements

The Auditors' report on the Group's financial statements for the year ended 31 December 2013 was not qualified.

Authorisation for issue

The interim financial statements have been approved for issue in accordance with a resolution of the Board of Directors dated 21 May 2014.